| Nov 22 |
Goldman Sachs: Biogen Inc. (BIIB) Is A Top Growth Investor Stock
|
| Nov 22 |
Biogen price target lowered to $207 from $251 at Mizuho
|
| Nov 20 |
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside
|
| Nov 20 |
Biogen Inc. (BIIB): Among the Best Genomics Stocks to Buy Right Now
|
| Nov 19 |
Biogen, UCB release phase 3 data on lupus candidate dapirolizumab
|
| Nov 19 |
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity
|
| Nov 18 |
Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026
|
| Nov 18 |
Needham downgrades Biogen on slow growth of Alzheimer's drug
|
| Nov 18 |
Biogen cut to hold by Needham on lack of catalysts, slow Leqembi sales
|
| Nov 18 |
Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™
|
